Arbutus Biopharma Corporation · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-15$4.95 RISE2026-02-05$3.67 PEAK2026-03-04$4.75 79d | -25.9% 52d | Missed | Missed | — | — | +29.4% 27d | Missed |
DROP2025-09-11$4.90 RISE2025-10-10$4.11 PEAK2025-12-15$4.95 95d | -16.1% 29d | Missed | Missed | — | — | +20.4% 66d | Missed |
DROP2024-12-10$3.76 RISE2025-04-08$2.88 PEAK2025-05-01$3.61 142d | -23.4% 119d | Missed | Missed | — | — | +25.3% 23d | Missed |
DROP2024-06-05$3.63 RISE2024-06-20$2.95 PEAK2024-09-10$4.56 97d | -18.7% 15d | Missed | Missed | — | — | +54.6% 82d | Missed |
DROP2023-06-16$2.49 RISE2023-10-23$1.69 PEAK2024-01-02$2.59 200d | -32.1% 129d | Missed | Missed | — | — | +53.3% 71d | Missed |
DROP2022-11-18$2.85 RISE2022-12-28$2.22 PEAK2023-03-27$3.06 129d | -22.1% 40d | Missed | Missed | — | — | +37.8% 89d | Missed |
DROP2022-06-23$2.92 RISE2022-09-26$1.88 PEAK2022-11-18$2.85 148d | -35.6% 95d | Missed | Missed | — | — | +51.6% 53d | Missed |
DROP2022-04-04$3.17 RISE2022-08-01$2.20 PEAK2022-08-04$2.54 122d | -30.6% 119d | Missed | Missed | — | — | +15.5% 3d | Missed |
DROP2022-01-03$3.98 RISE2022-05-10$1.98 PEAK2022-06-23$2.92 171d | -50.3% 127d | Missed | Missed | — | — | +47.5% 44d | Missed |
DROP2021-09-27$4.62 RISE2022-01-27$2.42 PEAK2022-02-09$3.41 135d | -47.6% 122d | Missed | Missed | — | — | +40.9% 13d | Missed |
DROP2021-09-27$4.62 RISE2021-11-22$3.11 PEAK2021-12-01$4.61 65d | -32.7% 56d | Missed | Missed | — | — | +48.2% 9d | Missed |
DROP2021-03-16$3.81 RISE2021-07-15$2.65 PEAK2021-09-24$4.62 192d | -30.4% 121d | Missed | Missed | — | — | +74.3% 71d | Missed |
DROP2021-03-16$3.81 RISE2021-07-14$2.65 PEAK2021-09-24$4.62 192d | -30.4% 120d | Missed | Missed | — | — | +74.3% 72d | Missed |
DROP2021-02-08$4.84 RISE2021-05-13$2.50 PEAK2021-06-08$3.44 120d | -48.3% 94d | Missed | Missed | — | — | +37.6% 26d | Missed |
DROP2020-12-15$4.97 RISE2021-03-04$3.14 PEAK2021-03-16$3.81 91d | -36.8% 79d | Missed | Missed | — | — | +21.3% 12d | Missed |
1–15 / 20 1 / 2 | |||||||
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage
Arbutus Biopharma Corporation reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 179.13 million compared to USD 1.76...
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from
WARMINSTER, Pa. — WARMINSTER, Pa. — Arbutus Biopharma Corp. on Wednesday reported first-quarter net income of $169.7 million, after reporting a loss in the same period a year earlier. On a...
Arbutus Biopharma targets chronic hepatitis B with Imdusiran, addressing a vast, unmet medical need. Read more on ABUS stock here.
Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.
Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international markets
The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international markets
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the best biotech penny stocks to buy in 2026. On March 23, Arbutus Biopharma concluded 2025 in a robust financial position, reporting $91.5 million in cash, cash equivalents, and marketable securities as of December 31. The company narrowed its annual net loss to $33.5 million ($0.17 per share), […]
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the best biotech penny stocks to buy in 2026. On March 23, Arbutus Biopharma concluded 2025 in a robust financial position, reporting $91.5 million in cash, cash equivalents, and marketable securities as of December 31. The company narrowed its annual net loss to $33.5 million ($0.17 per share), […]
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, a step that could help accelerate its development and review timeline. On […]
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, a step that could help accelerate its development and review timeline. On […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABUS | +5.56% | -2.36% | -5.20% | +35.71% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.59% | +3.36% | -1.75% | +23.03% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.34M | $28.54M | 0.00% | Added+7.4% | 2026-03-31 |
| Wellington | fundamental | 440.9K | $1.98M | 0.00% | Trimmed-7.0% | 2026-03-31 |
| FidelityFMR | fundamental | 145.1K | $653.07K | 0.00% | Added+6.3% | 2026-03-31 |
| DEShaw | quant | 143.2K | $644.40K | 0.00% | Trimmed-38.2% | 2026-03-31 |
| TRowePrice | fundamental | 116.0K | $522 | 0.00% | Added+30.0% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-02 | Androski Lindsay | President and CEO | A Grant / award(deriv) | 71,700 | — | +$0 |
| 2026-02-02 | Androski Lindsay | President and CEO | A Grant / award | 28,000 | — | +$0 |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | A Grant / award(deriv) | 188,400 | — | +$0 |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | A Grant / award | 73,500 | — | +$0 |
| 2025-08-06 | Sawhney Roger | Director | A Grant / award(deriv) | 157,600 | — | +$0 |
| 2025-03-31 | Nguyen Tuan | Chief Financial Officer | A Grant / award(deriv) | 750,000 | — | +$0 |
| 2025-03-20 | Androski Lindsay | President and CEO | A Grant / award(deriv) | 310,422 | — | +$0 |
| 2025-03-20 | Beardsley Robert A | Director | A Grant / award(deriv) | 157,600 | — | +$0 |
| 2025-03-20 | Hasija Anuj | Director | A Grant / award(deriv) | 157,600 | — | +$0 |
| 2025-02-19 | Sims Karen | Chief Medical Officer | A Grant / award(deriv) | 200,300 | — | +$0 |
| 2025-02-19 | Sims Karen | Chief Medical Officer | A Grant / award | 49,300 | — | +$0 |
| 2025-02-19 | HASTINGS DAVID C | Chief Financial Officer | A Grant / award(deriv) | 365,800 | — | +$0 |
| 2025-02-19 | HASTINGS DAVID C | Chief Financial Officer | A Grant / award | 90,100 | — | +$0 |
| 2025-02-19 | McElhaugh Michael J. | Interim President & CEO | A Grant / award(deriv) | 718,800 | — | +$0 |
| 2025-02-19 | McElhaugh Michael J. | Interim President & CEO | A Grant / award | 177,000 | — | +$0 |
| 2025-02-19 | Naftzger J. Christopher | General Counsel and CCO | A Grant / award(deriv) | 220,300 | — | +$0 |
| 2025-02-19 | Naftzger J. Christopher | General Counsel and CCO | A Grant / award | 54,300 | — | +$0 |
| 2025-02-05 | Naftzger J. Christopher | General Counsel and CCO | S Open-market sale | 11,333 | $3.28 | −$37.2K |
| 2025-02-05 | McElhaugh Michael J. | Interim President & CEO | S Open-market sale | 23,790 | $3.28 | −$78.1K |
| 2025-02-05 | Sims Karen | Chief Medical Officer | S Open-market sale | 19,348 | $3.28 | −$63.5K |
| 2025-02-05 | HASTINGS DAVID C | Chief Financial Officer | S Open-market sale | 22,183 | $3.28 | −$72.8K |
| 2024-08-16 | MANCHESTER KEITH S | Director | M Option exercise(deriv) | 54,915 | — | +$0 |
| 2024-08-16 | MANCHESTER KEITH S | Director | S Open-market sale | 8,846 | $3.69 | −$32.6K |
| 2024-08-16 | MANCHESTER KEITH S | Director | M Option exercise | 54,915 | $0.56 | +$30.8K |
| 2024-05-24 | Torti Frank | Director | A Grant / award(deriv) | 67,000 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.05 | — | — |
| 2026-05-13 | -0.03 | 1.19 | +4363.61% |
| 2026-03-23 | -0.05 | -0.01 | +75.05% |
| 2025-11-13 | -0.05 | -0.06 | -21.76% |
| 2025-08-06 | -0.09 | 0.01 | +115.23% |
| 2025-05-14 | -0.15 | -0.18 | -18.14% |
| 2025-03-27 | -0.12 | -0.10 | +14.48% |
| 2024-11-06 | -0.13 | -0.14 | -6.91% |
| 2024-08-01 | -0.13 | -0.15 | -16.93% |
| 2024-05-02 | -0.15 | -0.14 | +10.46% |
| 2024-02-29 | -0.16 | -0.16 | -1.82% |
| 2023-11-07 | -0.15 | -0.16 | -10.14% |
| 2023-08-03 | -0.14 | -0.13 | +7.40% |
| 2023-05-04 | -0.18 | -0.14 | +24.65% |
| 2023-03-02 | -0.18 | -0.19 | -3.03% |
| 2022-11-09 | -0.18 | -0.16 | +9.66% |